BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
SUBSCRIBE
BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
BullScope
No Result
View All Result
Home Bargains & Bubbles

Boeing at $231: The Math Behind a Recovery Story the Market Has Already Priced

Moe Alsumidaie by Moe Alsumidaie
August 17, 2026
in Bargains & Bubbles
0
74
SHARES
1.2k
VIEWS
Share on XShare on LinkedInShare on Facebook

For most of the past five years, Boeing has been a company in the middle of a slow-motion correction. A pair of fatal 737 MAX crashes in 2018 and 2019 grounded its bestselling jet and rewired its relationship with regulators. Then a door plug blew out of a 737 MAX 9 in January 2024, and the FAA tightened its grip again. Through all of it, Boeing kept losing money, kept burning cash, and kept carrying a debt load that would make most CFOs lose sleep. The stock sat in the low $200s as recently as last week.

Then, on August 3, 2026, the FAA certified the 737 MAX 7 for commercial service, and Boeing’s shares jumped 8% in a single session. The question worth sitting with is whether that jump reflects a genuine change in the math, or whether the mood, meaning what the market is currently willing to pay, has run ahead of what the filed numbers can yet support.

In one breath

Boeing’s 2025 annual filing shows the company’s first positive earnings per share since 2018, but a $9.6 billion one-time gain from selling part of its software business did most of the heavy lifting. Strip that out, and the core commercial and defense operations are still losing money quarter by quarter. The stock trades at 82 times last year’s reported earnings, a multiple that assumes the recovery is already complete. Those two readings cannot both be right, and that disagreement is the story.

Four years of losses, then a number that needs explaining

The filed record is worth reading slowly. From 2021 through 2024, Boeing lost money every single year. The 2024 10-K shows a net margin of negative 17.8%, meaning Boeing lost roughly 18 cents on every dollar it brought in. That is not a rounding error. It is the kind of number that, sustained long enough, hollows out a balance sheet.

BullScope TerminalWant the full evidence sheet behind pieces like this?The terminal runs the complete workup: Boeing and 500+ other names, on the same official data.See the evidence engine →

Then 2025 looks startlingly different. The 2025 10-K reports revenue of $89.5 billion and the first positive earnings per share in seven years. But buried in the same filing is the explanation: Boeing recorded a $9.6 billion gain from divesting portions of its Digital Aviation Solutions business. That gain, roughly equal to what a mid-sized airline earns in a decade, flowed straight through to the bottom line. A gain that large, that singular, is not a run rate. It is a one-time event.

For a saver trying to read the underlying business, the 2025 headline figures are less a verdict than a distraction.

What Q2 2026 actually shows

The most recent filed period is the 10-Q for the quarter ended June 30, 2026. Boeing reported Q2 revenue of $24.6 billion, up meaningfully from the same quarter a year earlier, and delivered 171 commercial aircraft during the quarter. Those are real operational improvements, not accounting adjustments.

But the quarter also carried a GAAP loss per share, weighed down by a charge on the VC-25B program, the heavily customized Air Force One replacement that has become a reliable source of losses. The commercial airplanes division and the defense division both ran negative operating margins. The overall company operating margin for the quarter was barely positive, and only because the Global Services segment, the parts and maintenance business, carried the load.

Free cash flow for Q2 was positive at $631 million, which matters because cash is harder to massage than earnings. But for the first half of 2026 combined, free cash flow was still negative, meaning Q1 consumed more than Q2 produced. Boeing’s own full-year 2026 outlook, stated in the July 28 earnings release, calls for meaningful positive free cash flow, meaning the second half would need to do the heavy lifting. The math is achievable if production ramps hold. It is not yet achieved.

BullScope TerminalYou just read Boeing’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →

The debt that does not disappear quietly

As of June 30, 2026, Boeing carried $45.9 billion in total debt. The company made genuine progress reducing that balance in the first half of 2026, per the Q2 10-Q. But $45.9 billion is still more than half of what Boeing earns in an entire year of revenue, a weight that limits how much the company can invest in new programs or return to shareholders. Think of it as a household that earns $90,000 a year carrying a $46,000 credit card balance: manageable, but every dollar of interest is a dollar not spent on the house.

The backlog, at least, is a genuine asset. By Q2 2026, the earnings call cited more than 6,200 airplanes valued at $715 billion, a record. At current revenue run rates, that represents roughly eight years of work sitting in signed orders. It means demand is not the problem. Converting that backlog into delivered planes, and delivered planes into cash, is the problem.

What the mood is paying for

The math, meaning what the filed fundamentals show, is a company still losing money on its core manufacturing operations, carrying a debt load that took years to accumulate, and generating its first meaningful free cash flow in recent quarters. The mood, meaning what the market is currently paying, is a stock at $231 trading at 82 times last year’s reported earnings, a figure our data shows sits at the 81st percentile of Boeing’s own decade-long valuation history. In plain terms, the market is paying a near-record premium relative to Boeing’s own past, at a moment when the underlying operations are still in recovery.

On August 11, 2026, Argus upgraded Boeing to “Buy” with a price objective well above the current price, citing production execution and the backlog. The broader analyst consensus, per MarketBeat, sits around “Moderate Buy” with average targets in the mid-$270s. Their argument is that the operational recovery is real and the backlog provides visibility. That argument is not wrong. But it is a forecast, not a filed fact, and the filed facts still show negative operating margins in the two divisions that build airplanes.

On August 12, 2026, shares slipped more than 1% after July delivery data showed a sharp month-over-month drop in jet deliveries. A single month’s data is not a trend. But it is a reminder that the path from backlog to cash is not a straight line.

BullScope TerminalBoeing was the article. The engine is the product.Same yardsticks, any ticker: filed financials in, math-vs-mood out. Nothing here is advice; it is the evidence, organized.Run another company →

For anyone trying to understand what the filed numbers say about today’s price, the honest answer is that the math describes a company in genuine transition, not one that has completed it. The mood has priced the destination. The filings describe the journey.

Reading the numbers

  • Net margin, FY2024: negative 17.8%. A net margin is what a company keeps from each dollar of sales after every cost, including interest on debt and taxes. Negative 17.8% means Boeing lost about 18 cents on every dollar it took in during 2024. For context, a grocery store earning a 2% margin is considered normal. Boeing was losing nine times that, in reverse. Source: 2024 10-K.
  • FY2025 EPS: $2.48, boosted by a $9.6 billion divestiture gain. Earnings per share is the profit divided across every share outstanding. A $9.6 billion one-time gain is like a household selling its vacation home and counting the proceeds as salary. It improves the year’s number without changing the underlying income. Source: 2025 10-K.
  • Q2 2026 free cash flow: $631 million positive. Free cash flow is the cash left after paying for the factories, tools, and equipment needed to run the business. It is harder to manipulate than reported earnings. $631 million for a single quarter is real progress, but the first half combined was still negative $823 million, meaning Q1 consumed more than Q2 produced. Source: Q2 2026 10-Q.
  • Total debt, June 30, 2026: $45.9 billion. At $89.5 billion in annual revenue, that debt is roughly six months of the entire company’s sales. A household earning $90,000 a year with $45,000 in debt is not insolvent, but every interest payment crowds out other choices. Source: Q2 2026 10-Q.
  • P/E ratio: 82.3, at the 81st percentile of Boeing’s own decade. A P/E ratio, or price-to-earnings multiple, is the price tag the market puts on each dollar of profit. Think of it as how many years of current earnings a buyer is paying upfront. At 82 times earnings, the market is paying 82 years’ worth of 2025 reported profit, at a moment when that profit was largely a one-time event. Our data places this at the 81st percentile of Boeing’s own ten-year history, meaning the stock has been cheaper than this about 80% of the time over the past decade.
  • Backlog: $715 billion as of Q2 2026. A backlog is signed orders not yet delivered. At current revenue run rates, $715 billion represents roughly eight years of work. It is the strongest evidence that demand for Boeing’s planes is not the constraint. The constraint is building and delivering them fast enough to convert that paper into cash. Source: Q2 2026 earnings call.

For the standing yardsticks on Boeing: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Boeing.

Sources

  • Boeing 10-Q, quarter ended June 30, 2026 (SEC EDGAR)
  • Boeing 10-K, fiscal year ended December 31, 2025 (SEC EDGAR)
  • Boeing 10-K, fiscal year ended December 31, 2024 (SEC EDGAR)
  • Boeing Q2 2026 earnings release, July 28, 2026
  • Boeing Q2 2026 earnings call highlights (GuruFocus)
  • Argus upgrade to Buy, August 11, 2026 (MarketBeat)
  • Boeing Q2 2026 loss report (AlphaStreet)
  • Boeing Q2 2026 earnings analysis (247 Wall St)
BullScope publishes impersonal research for a general audience. Nothing here is personalized investment advice, and nothing here is a recommendation to buy or sell any security. As of publication, neither BullScope nor its operator holds a position in any security, covered or otherwise; we do not trade at all, and we accept no compensation from any company we cover. When a conflict of interest exists, we do not publish: companies that compensate our operator in any capacity, or about which our operator could hold nonpublic information, are barred from coverage automatically, as described in the conflicts policy in our methodology. Figures come from company filings and public data through our published methodology; forecasts are conditional scenarios, not predictions and not promises. Markets carry risk, including loss of principal. Consider your own situation, or consult a licensed adviser, before acting on anything you read.
BullScope TerminalYou just read Boeing’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →
Moe Alsumidaie

Moe Alsumidaie

Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.

Recommended For You

Abbott’s Split Personality: Revenue Climbs 14%, the Stock Falls Anyway

by Moe Alsumidaie
October 22, 2026
0

Abbott Laboratories spent most of the pandemic era as a Wall Street darling, its COVID test sales turning a steady healthcare conglomerate into a growth story. Then the...

Read moreDetails

The $14 Acquisition Price and the Arbitrage Gap the Market Is Pricing

by Moe Alsumidaie
October 16, 2026
0

The short version Sun Pharmaceutical agreed in April 2026 to buy Organon for $14.00 a share in cash, a deal Organon shareholders approved in July. The stock trades...

Read moreDetails

From $8 to $0.45: Ascend Wellness Is Generating Real Cash While the Market Prices It for Failure

by Moe Alsumidaie
October 14, 2026
0

The story, briefly The math, meaning what the filed numbers actually show, tells a story of a cannabis retailer that turned cash-flow positive in 2023 and has been...

Read moreDetails

ADMA Biologics: A Business Earning Real Money, Priced Like It Might Not

by Moe Alsumidaie
October 13, 2026
0

Six years ago, ADMA Biologics was losing nearly two dollars for every dollar it brought in. The company made a single class of medicine, plasma-derived immunoglobulins (proteins collected...

Read moreDetails

Viatris: The Stock Has Run 72% in a Year. The Filed Numbers Tell a More Complicated Story.

by Moe Alsumidaie
October 9, 2026
0

The share price is up 72% over the past twelve months. Revenue has fallen every single year since 2021. Those two facts belong to the same company, and...

Read moreDetails
Next Post

Evidence Sheet: Apple (AAPL)

Please login to join discussion
BullScope
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the Terminal
A BullScope product

Related News

Costco at $948: The Filed Numbers vs. What the Price Tag Demands

October 9, 2026

Merck Is Printing Money and Losing Money at the Same Time. Both Are True.

September 7, 2026

Meta’s Q2 Filing: The Quarter the Bill Arrived

July 30, 2026
BullScope

BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.

Prefer BullScope.ai on Google

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

No Result
View All Result
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.